Biosimilar Battle Plans: US Supreme Court Seeks Solicitor General's Views On Zarxio
This article was originally published in SRA
The US Supreme Court has called for the Solicitor General's views in litigation between Amgen Inc. and Sandoz Inc. over the biosimilar launch notification and patent dance provisions of the biosimilars statute1. The request indicates the court is interested in the issue and may take it up.
Register for our free email digests: